All Resources

Patented Medicine Prices Review Board (PMPRB) • December 05, 2022

The Suspension and Reformulation of the PMPRB Guidelines is Urgently Required: IMC Response to PMPRB 2022 Guidelines Proposals

Learn more | View

Private Drug Coverage • November 25, 2022

Cost Drivers: Analysis of Private Drug Plans in Canada 2022

Learn more | View

Access to Medicine • November 17, 2022

Innovative Agreements Framework

Learn more | View

Access to Medicine • November 10, 2022

Canadian Drug Access Pathway

Learn more | View

Patented Medicine Prices Review Board (PMPRB) • November 09, 2022

Letter to The Honourable Jean-Yves Duclos, P.C., M.P.

Learn more | View

Patented Medicine Prices Review Board (PMPRB) • November 09, 2022

Letter to The Hon. Chrystia Freeland, P.C., M.P.

Learn more | View

Patented Medicine Prices Review Board (PMPRB) • November 09, 2022

Letter to The Honourable Mary Ng, P.C., M.P.

Learn more | View

Patented Medicine Prices Review Board (PMPRB) • November 09, 2022

Ministerial PMPRB Guideline Letter to The Hon. François-Philippe Champagne, P.C., M.P.

Learn more | View

Economic Impact • October 07, 2022

Pre-Budget Consultations in Advance of the 2023 Budget

Learn more | View

Access to Medicine • July 06, 2022

Developing a Pan-Canadian Genomics Strategy: Innovative Medicines Canada Response

IMC supports the creation of a Pan Canadian Genomics Strategy (PCGS) to help Canada advance its international leadership and increase capacity in genomics through commercialization and adoption….

Learn more | View

Access to Medicine • February 12, 2022

Optimizing Patient Access to Precision Therapies: Preparing for the Emerging Era of Advanced Testing

Learn more | View

Access to Medicine • February 05, 2022

Bluesky Project

Reimagining Canada’s Approval and Reimbursement System for Innovative Medicines February 2022…

Learn more | View